YAP1 and uterine corpus sarcoma: These treatments could be an option for LM and specific uterine sarcoma subtypes, as enhanced collagen deposition and YAP activity are associated with undifferentiated uterine sarcoma and endometrial stromal sarcoma aggressiveness [21, 22].